Literature DB >> 8723678

CDKN2A (p16INK4A) somatic and germline mutations.

B Smith-Sørensen1, E Hovig.   

Abstract

The cell cycle is composed of a series of steps that can be negatively or positively regulated by various factors. A group of low-molecular-weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent kinases in mammalian cells. Inactivation of the CDKN2A gene (also known as p16INK4A and MTS1) attracted considerable interest after it was mapped to 9p21, a locus for familial melanoma. In an effort to standardize the information regarding human CDKN2A mutations detected in cancers, a database with information of 146 point mutations has been created. Cancer type, origin of cells, specific mutation, amino acid change, literature citation, and other data are provided for each mutation entry. Studies of biochemical and biological functions of both wild-type and mutant proteins are central to our understanding of the role of p16INK4a mutations in tumorigenesis, a summary of these studies is also included in the present update.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723678     DOI: 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

1.  NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor.

Authors:  Tsutomu Mori; Daisuke D Ikeda; Toshihiko Fukushima; Seiichi Takenoshita; Hideo Kochi
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

2.  Genetics of coronary artery disease: focus on genome-wide association studies.

Authors:  Linnea M Baudhuin
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

Review 3.  Hypermutability in carcinogenesis.

Authors:  B S Strauss
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

4.  Genomic sequencing of key genes in mouse pancreatic cancer cells.

Authors:  Y Wang; Y Zhang; J Yang; X Ni; S Liu; Z Li; S E Hodges; W E Fisher; F C Brunicardi; R A Gibbs; M-C Gingras; M Li
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

5.  Frequent homozygous deletions of the CDKN2A locus in somatic cancer tissues.

Authors:  Abdulaziz Hamid; Beniamin Petreaca; Ruben Petreaca
Journal:  Mutat Res       Date:  2019-04-25       Impact factor: 2.433

6.  p53 and p16INK4A mutations during the progression of glomus tumor.

Authors:  S Güran; E T Tali
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  Histone deacetylase inhibitors -Promising agents for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer-.

Authors:  Youichirou Matsuzaki; Yoshihiro Sowa; Tohru Hirose; Tomoya Yokota; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2003-11       Impact factor: 3.674

8.  INK4 Family -A promising target for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer.

Authors:  Youichirou Matsuzaki; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2005-03       Impact factor: 3.674

9.  Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women.

Authors:  Marina Kvaskoff; Sylvie Mesrine; Agnès Fournier; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon
Journal:  Arch Intern Med       Date:  2007-10-22

10.  TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.

Authors:  L Wang; P Zhang; D P Molkentine; C Chen; J M Molkentine; H Piao; U Raju; J Zhang; D R Valdecanas; R C Tailor; H D Thames; T A Buchholz; J Chen; L Ma; K A Mason; K-K Ang; R E Meyn; H D Skinner
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.